34th week of 2013 patent applcation highlights part 39 |
Patent application number | Title | Published |
20130216565 | VACCINES BASED ON PEPTIDES OF THE COMPLEMENT PROTEIN C5A - The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRAN-ISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23) under the provision that the peptide fragment does not consist of amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG (SEQ ID No: 22). | 2013-08-22 |
20130216566 | Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using - SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen. | 2013-08-22 |
20130216567 | AVIAN GROUP D ROTAVIRUS - The invention relates to a newly identified avian rotavirus D VP6 nucleotide sequence and uses thereof. | 2013-08-22 |
20130216568 | IMMUNOGENIC PROTEINS AND COMPOSITIONS - The invention provides proteins and compositions for the treatment and prevention of | 2013-08-22 |
20130216569 | VACCINE - The present invention provides a polypeptide comprising the amino acid sequence as shown as SEQ ID No. 1 or a homologue or fragment thereof, a nucleic acid capable of encoding such a polypeptide and a vaccine comprising such a polypeptide/nucleic acid. The vaccine may be used for the treatment and/or prevention of a disease associated with an apicomplexan parasite. | 2013-08-22 |
20130216570 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA - Disclosed are immunogenic conjugates which elicit an immune response to | 2013-08-22 |
20130216571 | Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine - The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria | 2013-08-22 |
20130216572 | IMMEDIATE PROTECTION AGAINST PATHOGENS VIA MVA - The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen. | 2013-08-22 |
20130216573 | INFLUENZA VIRUS REASSORTMENT - Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed. | 2013-08-22 |
20130216574 | KIT PROVIDING MULTIPLE UNMET THERAPEUTIC EFFECTS - The present invention discloses a unique kit for providing a combinational therapeutic product comprising a medical device and a pharmaceutical composition to treat mammal diseases. The medical device is to meet these unmet needs of cleansing out these harmful substances, such as viruses, multiple drug resistant bacteria, fungi, pollen, dusts, or excessive mucus. The pharmaceutical composition adds the required functions of anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, to have the added effect of the medical device. The method of using the combinational product is also disclosed. The new product can be used to prevent and treat a variety of diseases, such as common cold, drug resistant influenza, sinusitis, post nasal drip, virus-triggered asthma, or chronic obstructive pulmonary disease. In addition, the new kit and the process of use are safe and cost effective. | 2013-08-22 |
20130216575 | RECOMBINANT SUBUNIT DENGUE VIRUS VACCINE - The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients. | 2013-08-22 |
20130216576 | PNEUMOCOCCAL SEROTYPE 6D - Disclosed is a new and emerging serotype of | 2013-08-22 |
20130216577 | Methods And Compositions For The Dietary Management Of Autoimmune Disorders - The present invention describes the use of lactic acid bacteria, particularly lactic acid producing members of the genus | 2013-08-22 |
20130216578 | RECOMBINANT TRYPANOSOMA THEILERI PARASITE - The present invention relates to the field of the veterinary medicine of bovine animals. In particular the invention relates to a recombinant | 2013-08-22 |
20130216579 | METHODS AND COMPOSTITIONS FOR GENE EDITING OF A PATHOGEN - Disclosed herein are methods and compositions for genome editing of the malarial parasite | 2013-08-22 |
20130216580 | HETEROLOGOUS PRIME BOOST VACCINATION REGIMEN AGAINST MALARIA - Described are methods for inducing an immune response in a subject against an antigen from a malaria-causing parasite, preferably | 2013-08-22 |
20130216581 | Carbon Nanotube Compositions and Methods of Use Thereof - Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy. | 2013-08-22 |
20130216582 | SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN - The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral cavity (e.g. sublingual mucosa) combined with the administration of the unrelated antigen to either the respiratory tract, gastro-intestinal tract or skin in a simultaneous, contemporaneous, separate or sequential manner is provided. | 2013-08-22 |
20130216583 | VACCINE COMPOSITION COMPRISING AN ANTIGEN AND A PEPTIDE HAVING ADJUVANT PROPERTIES - The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R | 2013-08-22 |
20130216584 | COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELLS - The present invention relates to compositions and methods for producing dendritic cells and particularly to compositions and methods for producing immature dendritic cells that are immunocompetent. We describe a method of producing dendritic cells by cultivation of monocytes, characterised by at least one of: pre-treatment of a tissue culture surface with at least one of: a substantially plasma-free and serum-free pre-treatment medium, a pre-treatment medium comprising heparin, and a pre-treatment medium comprising a protein solution; adsorption of monocytes using at least one of: a substantially plasma-free and serum-free adsorption medium; cultivation of monocytes using a substantially plasma-free and serum-free cultivation medium. We also describe compositions including the dentritic cells and uses of the dentritic cells. | 2013-08-22 |
20130216585 | COMPOSITION AND METHODS FOR QUENCHING FREE RADICALS AND MODULATING INFLAMMATION - Compositions and methods useful in quenching free radicals, the compositions including dihydroquercetin, vitamin C and Arabinogalactan, specifically, larch arabinogalactan, effective to enhance the immune modulating properties of Larch Arabinogalactan by quenching the free radicals that initiate a cascade of oxidative stress and inflammation. | 2013-08-22 |
20130216586 | ANIMAL FEED COMPOSITIONS AND METHODS OF USING THE SAME - Immune function of an animal can be modulated by administration of a composition that includes beta glucan. The beta glucan can be derived from | 2013-08-22 |
20130216587 | POLARIZED SCORPION VENOM SOLUTION AND A METHOD FOR MAKING POLARIZED SCORPION VENOM SOLUTION - The present invention discloses a polarized dilute blue scorpion venom solution and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution provides treatment to various diseases and conditions such as relieving pain, improving immune-system responses, treating cancer, preventing cancer, improving quality of sleep, reducing inflammation, and minimizing negative biological response to chemotherapy and radiation treatment | 2013-08-22 |
20130216588 | INSULIN-GOLD NANOCLUSTER, PHARMACEUTICAL COMPOSITION FOR REDUCING BLOOD GLUCOSE COMPRISING THE SAME, AND METHOD FOR DETECTING ADIPOSE CELLS IN TISSUE BY USING THE SAME - An insulin-gold nanocluster, a pharmaceutical composition for treating diabetes comprising the insulin-gold nanocluster, and a method for detecting adipose cells in a tissue by using the insulin-gold nanocluster are provided. Herein, the insulin-gold nanocluster of the present invention comprises: a gold nanocluster, and insulin connecting to the gold nanocluster, wherein the insulin-gold nanocluster emits red fluorescence at maximized wavelength of 670 nm. | 2013-08-22 |
20130216589 | ORAL VACCINE FOR AQUATIC ANIMALS - The preset invention relates to an oral vaccine with an enhanced protective efficacy for aquatic animals comprising an antigen, which is expressed in | 2013-08-22 |
20130216590 | TOPICAL ANTIVIRAL FORMULATIONS FOR PREVENTION OF TRANSMISSION OF HSV-2 - The present invention relates to formulations of antiviral compounds, in particular [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), suitable for topical application, and to their use in the reduction of or prevention of acquisition and transmission of herpes simplex virus. | 2013-08-22 |
20130216591 | Composition and method for inducing antigen-specific tolerance using IgA - The aim of this invention is to induce and maintain tolerance to specific antigens with IgA (Immunoglobulin A). It is theoretically likely that the major role of IgA is to induce and maintain tolerance because: it binds to epitopes(determinants) on the antigens; it does not mount destruction nor elimination of antigens; almost all antigens in the small intestine are not immunogens but tolerogens; and it is more important to induce tolerance rather than to stimulate immune responses in the small intestine. In other words, IgA is the inhibitor that suppresses IgM-, IgG- and IgE-mediated immune responses. Therefore, In order to induce tolerance to an antigen, it is theoretically effective to administrate the antigen and immunoglobulin A antibodies that are binding to the epitopes of the antigen. | 2013-08-22 |
20130216592 | PARTICLES CONSISTING OF A CHITOSAN POLYELECTROLYTE COMPLEX AND OF AN ANIONIC POLYSACCHARIDE, AND HAVING IMPROVED STABILITY - The present invention relates to positively charged particles consisting of a chitosan polyelectrolyte complex and of an anionic polymer, characterized in that the chitosan has a degree of acetylation (DA) in the range of 35 to 49% and a mean molar mass by weight (Mw) in the range of 55 to 150 kg/mol, as well as to a method for preparing same. | 2013-08-22 |
20130216593 | SYSTEMS, METHODS, AND DEVICES FOR PLASMID GENE TRANSFECTION USING POLYMER-MODIFIED MICROBUBBLES - Thiolated polyethylenimine (PEI) polymers can be covalently attached to lipid shell microbubbles. The PEI polymer can be modified with polyethylene glycol (PEG) chains to improve biocompatibility. The covalent attachment of the PEI polymer to the microbubble shell can result from a bond between a free sulfhydryl group (SH) of the thiolated PEI and a free maleimide group on the microbubble shell. DNA can be electrostatically bound to the PEI polymers to form polyplexes. A plurality of the polyplex-microbubble hybrids can be injected into a patient and can be imaged via ultrasound. While circulating in the bloodstream, and in particular, within a region of interest, high-pressure, low-frequency acoustic energy can be applied, thereby causing destruction by cavitation. Such cavitation can transiently increase the permeability of the endothelial vasculature thereby allowing plasmid DNA of the polyplexes carried by the microbubbles to be delivered to targeted cells. | 2013-08-22 |
20130216594 | PREPARATION OF ORODISPERSIBLE FILMS - The invention relates to a process for preparing a composition, more particularly a pharmaceutical composition for oral administration, comprising the steps of forming a suspension of at least one pharmaceutical ingredient and a solvent or solvent mixture, the at least one pharmaceutical ingredient being insoluble or poorly soluble in the solvent or solvent mixture, the step of adding at least one gel former to the suspension, the at least one gel former being swellable in the solvent or solvent mixture, and, optionally, the step of swelling the suspension. | 2013-08-22 |
20130216595 | Soluble Tablet, Containing Abrasive Media - In order to obtain steady erosion from soluble tablets and particularly constant dispersion of contained abrasive media, the employment of magnesium oxide and transverse interlaced polyvinylpyrrolidone (PVP) in defined layers and the admixing of randomly scattered silicic acids is suggested. | 2013-08-22 |
20130216596 | NANOCAPSULES CONTAINING MICROEMULSIONS - Delivery system based on polymeric nanocapsules which contain microemulsions, and their use in the preparation of pharmaceutical, cosmetic and/or alimentary compositions. | 2013-08-22 |
20130216597 | Pigments - The present invention relates to pigments based on multicoated flake-form substrates which are distinguished by the fact that at least 8 layers [layers (A)-(H)] are on the substrate, where an SiO | 2013-08-22 |
20130216598 | ANTIMICROBIAL FIBRE, FABRIC AND WOUND DRESSING CONTAINING NANO METAL AND THE PREPARATION METHOD THEREOF - The present invention discloses an antimicrobial fibre, fabric and wound dressing that incorporate nano metal and the preparation method thereof. Nano metal particles are homogenously distributed within the fibre structure or surface, and, the fibre does not contain protective colloid for the prevention of agglomeration of nano metal particles. The nano metal particles are in an amount of 1.1% to 20% by weight. The fibrous wound dressing has the ability to continuously release sufficient amount of silver ions and is especially suitable for the management of chronic wounds. It can effectively prevent various bacteria and microbial infections. | 2013-08-22 |
20130216599 | ANTIMICROBIAL PARYLENE COATINGS AND METHODS OF DEPOSITING SAME - Antimicrobial parylene coatings and methods for their vapor-phase deposition. | 2013-08-22 |
20130216600 | ANTIMICROBIAL NANOPARTICLE CONJUGATES - The present invention provides antimicrobial nanoparticle conjugates and an efficient method of preparing same. In particular, the invention relates to the preparation of antifungal nanoparticle conjugates comprising amphotericin B covalently immobilized to nanoparticles. The conjugates, and suspensions thereof, can be used to form antifungal coatings with particular application to medical devices and materials. | 2013-08-22 |
20130216601 | THREE-DIMENSIONAL BONE IMPLANT AND METHOD FOR PRODUCING SAME - A method for ex vivo production of a three-dimensional bone implant adapted for implantation to a patient, implants produced by such a method, and uses of such implants. The method comprises disposing differentiated osteoblasts on a matrix support comprising at least one of collagen, calcium phosphate, calcium sulfate and tricalcium phosphate; contacting the differentiated osteoblasts on the matrix with autologous blood serum from the patient, comprising at least one of a growth factor and a cytokine; and disposing the differentiated osteoblasts on the matrix support and the medium in a bioreactor, in which production of the bone implant is performed. | 2013-08-22 |
20130216602 | CLONIDINE COMPOUNDS IN A BIODEGRADABLE POLYMER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a drug depot at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate drug depot formulations are provided within biodegradable polymers, this pain relief can be continued for at least fourteen days. | 2013-08-22 |
20130216603 | PHARMACEUTICAL COMPOSITIONS AND DELIVERY DEVICES COMPRISING STINGING CELLS OR CAPSULES - A pharmaceutical composition is provided. The pharmaceutical composition comprises as an active ingredient a tropane alkaloid drug or a muscarinic receptor antagonist and stinging cells or capsules. | 2013-08-22 |
20130216604 | POLYPEPTIDE FOR INHIBITING METASTASIS, USES THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - A polypeptide for inhibiting, treating or diagnosing metastasis and an use thereof are disclosed, wherein the polypeptide is a polypeptide, a derivative polypeptide, or a mutated polypeptide of a fibronectin-binding domain of dipeptidyl peptidase IV. In addition, a pharmaceutical composition treating or diagnosing metastasis is also disclosed, which comprises the aforementioned polypeptide, and a pharmaceutically acceptable carrier. | 2013-08-22 |
20130216605 | MICRO-RNAS MODULATING IMMUNITY AND INFLAMMATION - MicroRNAs are shown to be up- and/or down-regulated in inflammation and immune cells using a mouse model of asthma and regulatory T cells as source of RNA, respectively. Modulating the expression of these microRNAs can be effective in redirecting inflammation and immunity and hence, can be beneficial as biomarkers or as therapeutic agents against diverse human immunologic and inflammatory diseases. | 2013-08-22 |
20130216606 | LIPOSOMAL FORMULATION FOR OCULAR DRUG DELIVERY - The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2μπι. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof. | 2013-08-22 |
20130216607 | ZWITTERIONIC LIPIDS - In various embodiments, the present invention provides zwitterionic lipids, encapsulants incorporating these zwitterionic lipids and such encapsulants encapsulating one or more bioactive agent. An exemplary bioactive agent is a nucleic acid. Also provided are pharmaceutical formulations of the encapsulants and methods of using such formulations to deliver a bioactive agent to a subject in treating or diagnosing disease in that subject. | 2013-08-22 |
20130216608 | Airway Administration of Angiogenesis Inhibitors - The present invention provides methods for the local pulmonary treatment of lung metastases and/or primary lung cancer, such as squamous lung cancer and/or small cell lung cancer, using local deposition of one or more agents capable of inhibiting angiogenesis and/or an agent that acts as an active anti-cancer agent and/or an active anti-metastatic agent. The agent capable of inhibiting angiogenesis and/or which acts as an active anti-cancer agent and/or an active anti-metastatic agent is administered to a patient with cancer as a treatment of said metastasis and/or cancer or to extend the lifespan for said cancer patient with reduced systemic side-effects compared to other treatment forms. The agent capable of inhibiting angiogenesis and/or which acts as an active anti-cancer agent and/or an active anti-metastatic agent is administered intratracheal, intrabronchial, intraalveolar or broncioalveolar. Administration for example via inhalation of an aerosol or as a dry powder and/or administered as a bronchoalveolar lavage (BAL) an effective amount of the agent. | 2013-08-22 |
20130216609 | Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2013-08-22 |
20130216610 | BIPHASIC LIPID-VESICLE COMPOSITION AND METHOD FOR TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY - A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks. | 2013-08-22 |
20130216611 | THERAPEUTIC AGENT FOR FIBROID LUNG - Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent. | 2013-08-22 |
20130216612 | TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS - The invention relates to methods of targeted drug delivery of antiviral compounds, including, chemical agents (like nucleoside analogs or protease inhibitors) and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of antiviral compounds to intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to internalizing uptake receptors present on these cells, tissues and organs. Thereto, the antiviral compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to ligands that facilitate the specific binding to and internalization by these receptors. | 2013-08-22 |
20130216613 | CYTOMEGALOVIRUS GB ANTIGEN - The invention relates to a cytomegalovirus (CMV) gB polypeptide comprising at least a portion of a gB protein extracellular domain comprising a fusion loop 1 (FL1) domain and a fusion loop 2 (FL2) domain, wherein at least one of the FL1 and FL2 domains comprises at least one amino acid deletion or substitution. | 2013-08-22 |
20130216614 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR TREATING NUEROLOGIC DISORDERS - The present invention relates to methods and compositions for preventing and reducing amyloid deposition in a subject by administering to the subject a composition containing aTLR4 agonist free of endotoxin, where the composition does not contain beta amyloid. | 2013-08-22 |
20130216615 | Pharmaceutical Compositions Containing Dimethyl Fumarate - Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w. | 2013-08-22 |
20130216616 | CUSTOMIZED POLYPILLS HAVING HIGH DRUG LOADS - Patient-specific polypills, or similar drug products with potential to benefit from reduced need for bulking agent and preferably having multiple active ingredients, producible via appropriately adapted “micro-dosing” technologies not requiring fluid-jet or like substrate and solvent dependent approaches, having less need for excipient, particularly filler, so that the products may contain a larger number of different drug substances having a lower overall number or amount of excipient materials and/or may contain drug substances having comparatively less need for formulation development or pre-production processing and/or may contain fewer potential causes of side effects. | 2013-08-22 |
20130216617 | PHARMACEUTICAL COMPOSITIONS OF (R)-LANSOPRAZOLE - The present invention relates to stable pharmaceutical compositions of (R)-lansoprazole or pharmaceutically acceptable salts thereof and process of preparing the same. The invention particularly provides pharmaceutical compositions of optically active (R)-isomer of lansoprazole with at least two functional coating layers. | 2013-08-22 |
20130216618 | SOFT CAPSULE BASED ON STARCH AND A METHOD AND DEVICE FOR THE PRODUCTION THEREOF - A method for producing starch soft capsules comprises the following steps: preparing a mixture comprising starch, plasticizer and water, wherein more than 50 weight percent of the starch is present in the form of particles of granular starch; shaping the mixture to form a film in a shaping process; solidifying the mixture by increasing the temperature of the mixture during and/or after the shaping process by more than 5° C.; and shaping the film to form a soft capsule. Soft capsules produced by this method have starch particles bonded to one another. A device for performing this method comprises a shaping device to enable shaping of the starch material to form a film, and a heating device to perform a heat treatment to destructure the starch during and/or after the shaping. It comprises a rotary die device. | 2013-08-22 |
20130216619 | PHARMACEUTICAL COMPOSITION OF ATORVASTATIN AND EZETIMIBE - The present invention relates to an oral pharmaceutical composition comprising: a) a core comprising atorvastatin or a pharmaceutically acceptable salt thereof and an alkalizing agent; b) an intermediate coating over the core; and c) an outer coating comprising ezetimibe. | 2013-08-22 |
20130216621 | BIFUNCTIONAL CONJUGATE COMPOSITIONS AND ASSOCIATED METHODS - Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size of the Signal-2 moiety and the second polymer carrier is about 1 nanometer to about 500 nanometers. In some embodiments, the Signal-1 moiety and the Signal-2 moiety are bound to the same polymer carrier. Associated methods are also provided. | 2013-08-22 |
20130216622 | MODIFIED BETA-LACTAMASES AND METHODS AND USES RELATED THERETO - The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. | 2013-08-22 |
20130216623 | APPARATUS AND FORMULATIONS FOR SUPRACHORIDAL DRUG DELIVERY - Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region. | 2013-08-22 |
20130216624 | SUSTAINED-RELEASE PELLETS CONTAINING TACROLIMUS AS AN ACTIVE INGREDIENT - The present invention relates to sustained-release pellets containing tacrolimus as an active ingredient. The sustained-release pellets of the present invention have multiple layers of hydroxypropyl methylcellulose, and may control the release of drugs by specific contents of hydroxypropyl methylcellulose and Surelease™, thus rendering the dissolution rate thereof uniform and stable, and enabling the dissolution rate to be adjusted as desired. The entire process for preparing the pellets of the present invention is carried out in a single fluidized-bed granulator, and therefore the preparation process is simplified and the time required for preparation is shortened while obtaining sustained-release pellets having uniform particle size distribution and contents. The sustained-release pellets of the present invention may have medicinal effects that last up to 24 hours, and therefore may be administered just once a day, thus improving patient compliance. Therefore, the pellets of the present invention may be effectively used in an orally administered pellet formulation containing tacrolimus as an active ingredient. | 2013-08-22 |
20130216625 | TREATMENT OF INSULIN RESISTANCE OR DISEASES ASSOCIATED WITH INSULIN RESISTANCE - The present invention relates to the use of a substance with the core structure of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the manufacture of a composition for the treatment of insulin resistance or diseases associated with insulin resistance, preferably in human subject in a daily dosage in a range of from about 5 mg to about 1500 mg. The invention furthermore relates to a method of treating insulin resistance or diseases associated with insulin resistance in a mammal, said method comprises administering to said mamma, preferably a human subject, a substance with the core structure of formula (I), preferably in a daily dosage in a range from about 5 mg to about 1500 mg. The substance is preferably isosteviol or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. Examples of diseases associated with insulin resistance and e.g. type 2 diabetes mellitus, insulin resistance syndrome, impaired glucose tolerance, the metabolic syndrome, hyperglycemia, hyperinsulinemia, arterioselerosis, hypercholesterolemia, hypertriglyeridemia, hyperlipidemia, dyslipidemia, obesity, central obesity, polycystic ovarian syndrome, hypercoagulability, hypertension, microalbuminuria, or any combinations thereof. | 2013-08-22 |
20130216626 | PLATELET-RICH PLASMA COMPOSITIONS - The present invention relates to a method of treating functional disability and/or pain associated with joints, tendons or connective tissue diseases, disorders or injuries comprising oral administration of a composition comprising heterologous platelet-rich plasma. The invention also relates to pharmaceutical compositions and nutritional compositions comprising heterologous platelet-rich plasma and uses thereof. | 2013-08-22 |
20130216627 | Portable Oxygen Enrichment Device and Method of Use - Lightweight, small, portable devices and methods are disclosed that provide oxygen-enriched air using an ultra rapid adsorption cycle based on advanced molecular sieve materials. | 2013-08-22 |
20130216628 | COMPOSITIONS OF HYPOCHLOROUS ACID (HOCI) AND METHODS OF MANUFACTURE THEREOF - The invention generally relates to compositions of hypochlorous acid (HOCl) and methods of manufacture thereof. In certain aspects, the invention provides air-free compositions of HOCl. In other aspects, the invention provides methods of making HOCl that involve mixing together in water in an air-free environment, a compound that generates a proton (H | 2013-08-22 |
20130216629 | BIO-MATERIAL COMPOSITION AND METHOD FOR SPINAL FUSION - The present invention relates to a material and method for providing spinal fusion. One preferred method comprises: accessing the intervertebral space defined between adjacent vertebrae; mixing magnesia, potassium biphosphate, and a calcium phosphate with an aqueous solution forming an activated spinal fusion slurry (ASFS); applying an effective amount of the ASFS to the intervertebral space between adjacent vertebrae; allowing the ASFS to set forming a bonded vertebrae structure; permitting bone growth into the bonded vertebrae structure providing fusion of the two adjacent vertebrae. | 2013-08-22 |
20130216630 | BIOMATERIALS FOR USE IN METHODS OF BONE REPLACEMENT THERAPY - This invention relates to biomaterials, said biomaterials for use in methods to control and/or induce bone growth. Particularly, the invention relates to macroporous calcium phosphate biomaterials pre-loaded with certain amounts of osteoclastic activity inhibitors for use in methods to control and/or induce bone growth in primates. | 2013-08-22 |
20130216631 | TARGETED PERFORMANCE OF HYPOHALITE COMPOSITIONS THEREOF - This invention relates to extend the benefits of using hypochlorite compounds such as sodium hypochlorite to clean and disinfect articles while reducing or eliminating the side effects of treating an article with a strong oxidant material. The invention relates to a single step process involving mixing of precursor compositions of a suitable hypohalite or hypohalous acid with a solution of a reducing agent. Optionally a buffer may be present in either or both precursor compositions, such that at time of use such active hypohalous acid concentration in the resulting aqueous mixture remains at a sufficient activity level to effect one or more desired benefits against a target substrate for a desired period of time. The oxidant is substantially consumed by reaction with the reducing agent after the time needed for achieving the desired benefit has passed. | 2013-08-22 |
20130216632 | Method for Controlling Hair Growth, Method for Selecting or Evaluating Hair Growth Control Agent, and Hair Growth Suppression Agent - The present invention provides a method for controlling hair growth, a method for selecting or evaluating a hair growth control agent, and a hair growth suppression agent. The present invention provides a method for selecting or evaluating a hair growth control agent, including the steps of administering a test substance to a cell capable of expressing DnaJC6; measuring the expression of DnaJC6 in the cell; and evaluating the controlling effect of the test substance on hair growth based on the expression. The present invention also provides a hair growth suppression agent containing funabarasou ( | 2013-08-22 |
20130216633 | Articles and Compositions for Enhancing Sports Scores - Methods and compositions for enhancing the score of an individual in a sport activity are disclosed. | 2013-08-22 |
20130216634 | Herbal Supplement Prepared From Pelargonium Citronellum - An extraction method for extracts of | 2013-08-22 |
20130216635 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS - Disclosed are compositions and corresponding methods of their use that include an extract from | 2013-08-22 |
20130216636 | TOPICAL SKIN CARE FORMULATIONS COMPRISING JABOTICABA AND CASHEW FRUIT PULPS AND EXTRACTS THEREOF - Disclosed are compositions and corresponding methods of their use that include jaboticaba fruit pulp and/or cashew fruit pulp or extracts thereof. | 2013-08-22 |
20130216637 | INDUCTION OF A PHYSIOLOGICAL DISPERSION RESPONSE IN BACTERIAL CELLS IN A BIOFILM - The present invention is directed to a compound which induces a physiological dispersion response in bacterial cells in a biofilm. The present invention is also directed to compositions containing this compound, methods of isolating the compound, and uses thereof. | 2013-08-22 |
20130216638 | Molding Apparatus and Method - A molding apparatus for making a continuous molded article or continuous series of molded articles generally includes a pair of spaced-apart molding assemblies, which cooperatively generate a movable mold having a dynamic mold-cavity therein, each of the molding assemblies including a series of movable mold segments, which are adapted to fit together to form a portion of the dynamic mold-cavity, a drive mechanism for conveying the mold segments along a path, and a dispenser for dispensing a moldable, expandable material into the dynamic mold-cavity. | 2013-08-22 |
20130216639 | PRODUCTION OF COOKIES HAVING LARGE PARTICULATES USING ULTRASONIC WIRECUTTING - A method for the continuous production of cookies having a high content of large inclusions, such as chocolate chips, nuts, and fruit pieces includes extruding a cookie dough containing the inclusions through a die orifice to obtain an extrudate dough rope, and cutting the extrudate dough rope with an ultrasonic cutting blade. The ultrasonic cutting severs the extrudate dough rope into dough pieces which fall onto a moving conveyer into a substantially uniform or regular array for uniform baking. The ultrasonic cutter is controlled to provide a roughened top surface on a dough piece to provide a home baked appearance upon baking, while cutting through the inclusions without substantial displacement of the inclusions which would cause pock marks on the surface of the dough piece, and without substantial dough piece weight variation. | 2013-08-22 |
20130216640 | Disc-shaped retaining device for bushings of a rotary tablet press - The invention concerns a disc-shaped retaining device for bushings of a rotary tablet press, wherein the disc-shaped retaining device comprises two disc halves that are connected with one another, each of which shows multiple holes, which align with one another if the disc halves are connected with one another and thus form mounting holes in which one respective bushing is located, wherein the bushings between the disc halves that are connected with one another are designed in a form-fit manner. | 2013-08-22 |
20130216641 | MOLD ROLLER AND METHOD OF MANUFACTURING SUCH - A mold roller and a method of manufacturing the mold roller comprising heating a metal substrate which has a microstructure pattern and attaching an ethylene tetrafluoroethylene (ETFE) film on the heated metal substrate. The ETFE film is pressed on the heated metal substrate and the microstructure pattern is thereby transferred and formed on a first side of the ETFE film The FIFE film with the microstructure pattern is than transferred to a circumferential surface of a core roller by a roller-to-roller process as its second side opposite to the first side attached to the circumferential surface. | 2013-08-22 |
20130216642 | TRANSPORT DEVICE AND TRANSPORT METHOD FOR CONTAINER TREATMENT PLANT AS WELL AS BLOW MOLDING MACHINE - A transport device and a transport method for a container treatment plant as well as a blow molding machine is provided. The transport device comprises at least one transport star for transporting receptacles to or away from a treatment station of the container treatment plant, wherein the at least one transport star is arranged obliquely to the treatment station. | 2013-08-22 |
20130216643 | SPLIT MOLD INSERT FOR FORMING A NECK PORTION OF A PREFORM AND THE MOLD STACK INCORPORATING SAME - There is disclosed a neck ring ( | 2013-08-22 |
20130216644 | HOT RUNNER NOZZLE HAVING AN ELECTRICAL HEATING ELEMENT - A hot runner nozzle having an electrical heating element includes a connector for producing an electrical connection to a connection line, terminal contacts for the heating element terminating in an insulation body for the connector that separates the terminal contacts from one another electrically. The connection line has contact elements that are electrically contactable with the terminal contacts of the heating element. The insulation body is arranged at least in part in a receiving sleeve of the connector, that the connection line may be fixed in or on the receiving sleeve such that the contact elements of the connection line electrically contact the terminal contacts of the heating element, and that a first end of the receiving sleeve that faces towards the heating element wraps around the insulation body and has on this first end two opposing feet that face outward and that are attached to the heating element. | 2013-08-22 |
20130216645 | APPARATUS FOR DEMOLDING MOLDED PARTS - A device removes molded parts from a mold cavity of a mold half of an injection molding machine. The device contains an ejection mechanism used to remove the molded parts from the mold cavity in an ejection direction. A receiving element is arranged in relation to the mold cavity in the ejection direction, the receiving element contains a receiving opening to which low pressure is applied. The receiving opening is connected to a supply opening of a chamber by a first line. The chamber contains a suction opening on a vertically arranged lateral wall, to which low pressure is applied. | 2013-08-22 |
20130216646 | Nanoparticles of Nutritional and Pharmaceutical Compounds - The invention relates to a composition in particle form having the structure: | 2013-08-22 |
20130216647 | METHODS FOR MAKING MILK-LIKE BEVERAGES - The invention provides methods for making a milk-like beverage compositions comprising creating a homogeneous aqueous mixture of (1) one or more caseinates, (2) whey protein, (3) one or more fats, (4) one or more hydrocolloids, and (5) one or more emulsifiers; heating the aqueous mixture to a temperature of from about 118 to about 127° C. and maintaining such temperature for from about 8 to about 14 minutes; and cooling the heated aqueous mixture to a temperature of from about 20 to about 35° C. The invention also provides the milk-like beverage compositions made using the methods. | 2013-08-22 |
20130216648 | CHEWING GUM COMPOSITIONS PROVIDING FLAVOR RELEASE PROFILES - A chewing gum composition including at least three flavor compositions providing a unique and long-lasting flavor sensations to the consumer. | 2013-08-22 |
20130216649 | MOUTH-MOISTENING GUM COMPOSITIONS AND PRODUCTS CONTAINING THE SAME - A chewing gum composition is disclosed that imparts a mouth-moistening effect when orally consumed by an individual. Specifically, the chewing gum composition comprises a blend of components comprising spilanthol to reduce or eliminate the perception of mouth dryness in an individual. The chewing gum composition can further include such components as a sweetening composition, a food-grade acid composition, and a cooling agent composition. | 2013-08-22 |
20130216650 | STEAMER DEVICE AND METHOD OF USE THEREOF - A steamer device and method of use thereof. More particularly, a steamer device (generally a vertical steam device) designed to make loading and unloading of rice, easy, quick, and efficient while ensuring a quality steam for the rice, similar to traditional saké steaming methods. | 2013-08-22 |
20130216651 | Process For Producing a Baked Product Having Increased Flavor Stability with Catalase and Phospholipase - The present invention relates to a process for producing a baked product having increased flavor stability comprising the steps of: (a) preparing a dough comprising flour, water, an enzyme preparation having catalase activity and an enzyme preparation having phospholipase activity; and (b) baking the dough to obtain the baked product. | 2013-08-22 |
20130216652 | INTRINSIC SUGAR REDUCTION OF JUICES AND READY TO DRINK PRODUCTS - The invention relates to a method of reducing the intrinsic sugar content in a food product such as a juice or a ready to drink sugar based product, by contacting the food product with sufficient amounts of at least one transglycosidase under conditions sufficient to enzymatically convert intrinsic sugars in the food product to non-digestible carbohydrates and non-digestible oligosaccharides, such as fructo-oligosaccharides, and gluco-oligosaccharides to thus form a more nutritional product. The invention also relates to nutritional food products produced by the methods of the invention. | 2013-08-22 |
20130216653 | SPORE SURFACE DISPLAY OF BIOACTIVE MOLECULES - The present invention relates to the display of bioactive molecules at the surface of spores for both in vitro and in vivo applications. Three small open reading frames (ORFs) have been identified which are very useful for display of bioactive molecules at the spore surface. The encoded small proteins have a molecular weight of less than 12 kDa, which corresponds to about less than 100 amino acids. | 2013-08-22 |
20130216654 | FOOD ADDITIVE COMPRISING AN AMIDASE FOR DETOXIFYING OCHRATOXIN - The present invention relates to amidase enzymes and a feed or food additive comprising the amidase enzyme capable of degrading ochratoxin. | 2013-08-22 |
20130216655 | FOAMING AGENTS COMPRISING HYDROPHOBIN - A food composition comprising a hydrophobin, a protein and/or polysaccharide and a corresponding denaturing enzyme is provided, wherein the activity of the denaturing enzyme has been substantially reduced. | 2013-08-22 |
20130216656 | Food Supplement - The invention discloses a food supplement, which includes at least the following components: omega-3 fatty acids; natural carotenoids; natural tocopherol; and tocotrienol. The carotenoids include carotenes. The carotenoids and tocotroniel are obtained from a Carotino mixed concentrate. The Carotino mixed concentrate is a natural tocotrienol (Vitamin E) and carotene oil complex derived from palm fruits. | 2013-08-22 |
20130216657 | FOOD-PRESERVATION DEVICES AND METHODS OF USE - Food packaging materials are provided. In some embodiments, foam sprayable material is provided. | 2013-08-22 |
20130216658 | TEXTURED, FREEZE-DRIED PRODUCTS AND METHODS FOR MAKING SAME - Textured, co-deposited, freeze-dried food products are provided, as well as methods of making same. In a general embodiment, the food products have a first component and a second component that are disposed adjacent one another. The first and second components may be the same or different materials and may have any number of distinguishable characteristics including, but not limited to, flavor, color, texture, optical properties, etc. The food products are subjected to a sublimation step during manufacturing to remove excess water in the food product to provide a freeze-dried food product. | 2013-08-22 |
20130216659 | FOOD PRODUCT AND COATING - The coating can have a low-sweetness perception. During manufacturing and processing, the coating maintains a flowability to allow a glaze state of the coating to be applied to a food. Upon cooling, the glaze state of the coating forms a glass state that provides a low-sweetness impact which facilitates application of savory taste perceptions. | 2013-08-22 |
20130216660 | EDIBLE CONTAINER FOR FOODSTUFFS AND PROCESS FOR PRODUCING THE SAME - An open-ended edible container for foodstuffs is provided. The open-ended container is composed of cereals and/or fruits in a sheet formed of a binder wherein the inner surface of the container is very lightly patterned while the outer surface has a smooth texture with embedded flakes. A process for manufacturing edible containers for foodstuffs is also provided and includes the steps of: pouring a liquid batter on baking plates, partially cooking the batter for providing a sheet, depositing cereals and/or fruit flakes as a layer onto the sheet, cooking the sheet, and giving the desired shape to the container. The inner surface of the container is very lightly patterned while the outer surface of the container has a rough texture with embedded flakes. | 2013-08-22 |
20130216661 | MULTI-REGION CONFECTIONERY - A dough-like confectionery material contains a solid particulate, a liquid, and a diffusion controller. The dough-like confectionery material is an effective replacement for panned coatings, and it can be applied to an edible substrate, such as candy or chewing gum to form a layered confection. Methods and apparatus for forming layered confections are also described. | 2013-08-22 |
20130216662 | OLIVE-BASED RECONSTITUTED PRODUCT AND PRODUCTION PROCESS - The present invention relates to the process of obtaining reconstituted foods from natural raw materials and the products obtained following said process. It relates particularly to the process of producing a reconstituted product comprising two concentrically distributed portions such that the outer portion comprises reconstituted olive and the inner portion comprises reconstituted pepper. | 2013-08-22 |
20130216663 | CAPSULE FOR PREPARATION OF A BEVERAGE - The present invention is directed to a capsule ( | 2013-08-22 |
20130216664 | CONTROLLING HEAT INDUCED FOAM GENERATION OF FOODSTUFF - The present invention relates to the use of a composition to control the degree of heat induced foam generation in a foodstuff system when said foodstuff system is heated, wherein the composition comprises polyglycerol polyricinoleic acid. | 2013-08-22 |
20130216665 | MULTIPLE EMULSIONS FOR COLORANTS - The present invention is related to a multiple emulsion of the water-in-oil-in-water (W/O/W) type for stabilization of natural coloring agents, such as anthocyanin, phycocyanin, | 2013-08-22 |